Welcome to our dedicated page for Akari Therapeutics Plc news (Ticker: AKTX), a resource for investors and traders seeking the latest updates and insights on Akari Therapeutics Plc stock.
Akari Therapeutics Plc (AKTX) is a clinical-stage biopharmaceutical company advancing innovative treatments for rare autoimmune and inflammatory diseases. This page provides investors and industry observers with timely updates on the company’s clinical developments, regulatory milestones, and strategic initiatives.
Access comprehensive coverage of AKTX’s progress, including press releases on trial results, FDA designations, and partnership announcements. Our curated news collection focuses on developments related to coversin, nomacopan, and other pipeline candidates targeting complement-mediated disorders.
Key updates include progress in treating conditions like HSCT-TMA and Geographic Atrophy, manufacturing partnerships, and scientific presentations. All content is verified from primary sources to ensure accuracy for investment research and market analysis.
Bookmark this page for centralized access to AKTX’s latest developments in complement system therapeutics. Check regularly for objective updates on clinical advancements and corporate announcements relevant to biopharmaceutical investors.
Akari Therapeutics (Nasdaq: AKTX) announced a patient has completed treatment in the Phase III clinical trial of nomacopan for pediatric HSCT-TMA, a serious post-stem cell transplant complication. Nomacopan, a bispecific inhibitor, shows promise as it is currently the only investigational therapy with Orphan Drug and Fast Track designations from the FDA. The trial aims to recruit seven pediatric patients in the U.S., U.K., and Poland. While one patient was discharged after over 60 days of treatment, another unfortunately died from unrelated complications. The mortality rate for severe HSCT-TMA is 80%. The study's primary endpoints focus on red blood cell transfusion independence and urine protein levels.
Akari Therapeutics, Plc (Nasdaq: AKTX) announced the appointment of Melissa Bradford-Klug as Chief Operating Officer, effective July 1, 2022. With over 25 years of experience across biotech and healthcare sectors, she will drive business development strategies and oversee the advancement of nomacopan, Akari's lead asset, targeting conditions like bullous pemphigoid. Bradford-Klug's appointment is expected to strengthen Akari's operational capabilities and accelerate clinical trials, enhancing the company's growth prospects and commitment to addressing unmet medical needs.
Akari Therapeutics (Nasdaq: AKTX) presented findings from its CASCADE and CORONET studies on COVID-19 pneumonia at the ATS 2022 Annual Meeting. The CASCADE study revealed elevated inflammatory biomarkers in COVID-19 pneumonia patients compared to healthy controls. The CORONET study demonstrated that 6 out of 7 hospitalized patients treated with the investigational drug nomacopan survived, showcasing its potential in reducing COVID-19 complications. No adverse effects were reported. The company focuses on therapies for autoimmune and inflammatory diseases, with nomacopan targeting complement activation.
Akari Therapeutics has initiated Phase III studies of nomacopan for pediatric hematopoietic stem cell transplant-related thrombotic microangiopathy and bullous pemphigoid, addressing critical unmet needs with no current approved treatments. The company's preclinical program for long-acting PAS-nomacopan shows promise in treating geographic atrophy/dry age-related macular degeneration. Financially, Akari reported a net loss of approximately $17.4 million for 2021, with cash reserves down to $9.4 million. The company increased manufacturing yield of nomacopan significantly, enhancing its development capabilities.
Akari Therapeutics (Nasdaq: AKTX) announced the presentation of two posters at the ATS 2022 Annual Meeting, highlighting findings from the CORONET and CASCADE studies related to COVID-19 pneumonia. The CORONET study assessed nomacopan's compassionate use in hospitalized patients, while the CASCADE study focused on biomarker correlations for risk stratification. Presentations are scheduled for May 17, 2022, at the Moscone Center in San Francisco. Akari aims to enhance understanding of inflammation's role in COVID-19, contributing valuable insights to the medical community.
Akari Therapeutics (Nasdaq: AKTX) announced positive Phase II results for nomacopan in treating bullous pemphigoid (BP), a severe autoimmune skin disease. In the study, nine patients received nomacopan; 77.8% responded, with three showing over 80% reduction in disease activity by day 42. Notably, no severe treatment-related adverse events were reported, underscoring nomacopan's safety. This research, published in JAMA Dermatology, supports further development of nomacopan, which could address the unmet need for effective therapies in BP.
Akari Therapeutics (Nasdaq: AKTX) presented promising preclinical results for PASylated-nomacopan at the ARVO 2022 Annual Meeting, focusing on its efficacy in treating geographic atrophy (GA) and choroidal neovascularization (CNV). The findings indicated that PAS-nomacopan significantly reduced CNV in animal models, with a potential dosing interval of three months, thereby addressing patient burden associated with frequent injections. Additionally, nomacopan showed effectiveness in reducing inflammation linked to ocular diseases compared to traditional treatments.
Akari Therapeutics (Nasdaq: AKTX) announced presentations at the ARVO 2022 Annual Meeting focusing on innovative treatments for age-related macular degeneration (AMD) and allergic conjunctival disease. Professor Virginia Calder will present findings on topical nomacopan, a dual inhibitor, while Dr. Wynne Weston-Davies will discuss the long-acting PAS-nomacopan for retinal diseases. Both presentations highlight the unmet need for effective therapies targeting complement and leukotriene pathways in ocular conditions. The event will take place in Denver, CO, from May 1-2, 2022.
Akari Therapeutics (Nasdaq: AKTX) announced new preclinical data for votucalis, a novel broad-acting antihistamine, which shows promise in treating pain and itch linked to conditions like atopic dermatitis and psoriasis. The data, published in Frontiers in Pharmacology, highlight votucalis's ability to inhibit all four histamine GPCRs, offering new treatment avenues not available with current antihistamines. The research indicates votucalis achieves effective local administration at lower doses, potentially reducing CNS-related side effects typical of opioids.
Akari Therapeutics has secured approximately $9.0 million through definitive agreements with institutional and accredited investors, including Chairman Dr. Ray Prudo. The company will issue roughly 7,500,000 American Depository Shares (ADSs) at $1.20 per ADS, accompanied by warrants for additional shares. The offering is expected to close around March 10, 2022, pending customary conditions. This offering is registered under an effective shelf registration statement with the SEC, aiming to bolster Akari's financial position for development of its drug candidate, Nomacopan.
FAQ
What is the current stock price of Akari Therapeutics Plc (AKTX)?
What is the market cap of Akari Therapeutics Plc (AKTX)?
